Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SGEGDFLAEGGGVR
Primary information
sequence IDSeq_7092
Peptide sequenceSGEGDFLAEGGGVR
CancerPDF_ID CancerPDF_ID7, CancerPDF_ID168, CancerPDF_ID639, CancerPDF_ID1025, CancerPDF_ID1216, CancerPDF_ID2301, CancerPDF_ID3256, CancerPDF_ID6835, CancerPDF_ID8503, CancerPDF_ID9668, CancerPDF_ID10093, CancerPDF_ID12183, CancerPDF_ID12687,
PMID16896061,19728888,19795908,16395409,21136997,21136997,21267442,24982608,23667664,21533267,21805675,26992070,25168216
Protein NameFibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinopeptide A,Isoform 1 of Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain
UniprotKB Entry NameFIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN
FluidSerum,Serum,Plasma,Serum,Serum,Plasma,Serum,Urine,Serum,Serum,Urine,Serum,Serum
M/Z1350.64,1350.6275,675.81,1350.64,1349.62116,1349.6212,1351,NA,1349.62,675.79,1350.6273,1349.6212,NA
Charge1,NA,2,1,1,1,NA,NA,1,2,NA,NA,NA
Mass (in Da)1350.63,NA,NA,NA,NA,NA,NA,NA,1351.42,NA,NA,1350.625048,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1349.62
Profiling TechniqueMALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,Nano-LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,LC-MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,MALDI-TOF-MS,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,NA,NA,Multiple Reaction Monitoring,NA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,NA,less than 7%,less than 1 “5,NA,0.001,NA,0.01,NA,1.49,1,FDR 1 %,NA
CancerPDF_ID CancerPDF_ID7, CancerPDF_ID168, CancerPDF_ID639, CancerPDF_ID1025, CancerPDF_ID1216, CancerPDF_ID2301, CancerPDF_ID3256, CancerPDF_ID6835, CancerPDF_ID8503, CancerPDF_ID9668, CancerPDF_ID10093, CancerPDF_ID12183, CancerPDF_ID12687,
p-Value1.00E-05,less than 0.01,NA,1.38E-14,3.54E-04,3.54E-04,NA,NA,NA,2.22E-22,NA,NA,9.82E_04
SoftwareMASCOT,MASCOT(v 2.0.04 for Windows),FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),NA,"GPM search engine, MASCOT",MASCOT,MASCOT,NA,SEQUEST and Maxquant,MASCOT
Length14,14,14,14,14,14,14,14,14,14,14,14,14
Cancer TypeMetastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy",Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Stomach adenocarcinoma,Ovarian cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Muscle-invasive bladder cancer,Melanoma,Renal cell carcinaoma
DatabaseNCBI refseq Protein Database,SwissProt Database (release 54.7),NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,IPI 3.71 Human Database ,NA,Swissprot Database (57.4),SwissProt Database,SwissProt Database,SwissProt Database
ModificationNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,41 and 21 patients are in training dataset and testing dataset respectively; 21 and 12 Normal healthy individual s are in training dataset and testing dataset respectively,6 Ovarian cancer patients and 6 normal individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control,8 cancer samples and 4 healthy samples,"30 RCC patients and 30 healthy controls for training dataset and 6 RCC patients, 6 control in independent validation dataset"
RegulationDifferentially expressed between cancer vs normal samples,"Differentially expressed between pre-treatment, after two cycles of treatment vs end of treatment",NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.47, 0.46 and 0.35 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,Differentially expressed between cancer vs normal,NA,Uniquely present in case of urine of ovarian cancer patients,NA,Differentially expressed between Lung cancer vs control,Differentially expressed between cancer vs normal samples,"Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples.",Upregulated in cancer v/s Normal
ValidationIndependent validation,NA,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,Independent validation,NA,NA,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic,na,Independent validation
Sensitivity95% on independent dataset,NA,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,0.898,0.898,NA,NA,NA,NA,NA,NA,100 % (for 19 peptide signatures)
Specificity95% on independent dataset,NA,NA,NA,0.946,0.946,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,NA,NA,97.5 % on validation dataset,NA,0.917,NA,NA,NA,0.815,NA,NA,AUC : 0.706
Peptide AtlasPeptideAtlas
IEDB462581